A Prospective Surveillance Trial to Evaluate the Safety of Optison in Clinical Practice.

• Status: Completed
• Trial end date: 2009-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This prospective surveillance trial will gather safety information for Optison when it is used in routine practice.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GE Healthcare

Criteria

Inclusion Criteria:

• The subject is over 18 years old.

• The subject has been scheduled for an Optison-enhanced echocardiography exam.

• The subject has provided signed and dated informed consent.

Exclusion Criteria:

• Known hypersensitivity to perflutren, blood, blood products or albumin.